MGI listed on STAR Market

CACLP 2022 Booth No.：A2-2009

On September 9, 2022, MGI Tech Co., Ltd. was listed on the STAR Market. The stock name is Huada Zhizao, the stock code is 688114. SH, with the issue price is 87.18 CNY / share, and the opening price is 107 CNY / share. MGI is an affiliated company of the Listed Company BGI. The two companies operate independently and belong to BGI group.

Financial data show that from 2019 to 2021, MGI achieved a revenue of 1.091 billion CNY, 2.78 billion CNY and 3.93 billion CNY. The net profit attributable to the parent company was -244 million CNY, 261 million CNY and 483 million CNY respectively. In 2020 and 2021, the company's income related to COVID-19 was 1.985 billion CNY and 2.344 billion CNY respectively, accounting for 71.41% and 59.67% of the current operating income, mainly from the laboratory automation business segment.

MGI focuses on the field of life science and biotechnology, with the R & D, production and sales of instruments and equipment, reagent consumables and other related products as its main business, and provides real-time, panoramic and full life-cycle digital life equipment and system solutions for precision medicine, precision agriculture, precision health and other industries.

Since its establishment in 2016, the company has mastered the core technologies in gene sequencing, library preparation, laboratory automation and other fields based on the technology of CG us, a wholly-owned subsidiary. As of December 31, 2021, the company has obtained 217 domestic patents and 258 overseas patents, including 102 invention patents, 78 utility model patents and 37 design patents.

From 2019 to 2021, the R & D investment of MGI was 343 million CNY, 700 million CNY and 608 million CNY, accounting for 31.46%, 25.19% and 15.48% of the operating income, respectively, higher than the level of the same industry.

In the field of gene sequencer, the company has formed a number of original core technologies represented by " DNBSEQ sequencing technology", "regular array chip technology" and "sequencer OPTO electromechanical system technology"; In the fields of library preparation, laboratory automation and other omics, core technologies such as "key library preparation technology", "automatic sample processing technology" and "remote ultrasonic diagnosis technology" have gradually developed. The company has initially established a global business network.

According to the prospectus, MGI plans to raise 2.528 billion CNY this time, which will be used for intelligent manufacturing and R & D base projects, R & D and production projects of gene sequencer and supporting equipment and reagents based on semiconductor technology, R & D center projects, marketing service center construction projects, information system construction projects and supplementary working capital.

About MGI:

MGI Tech Co., Ltd. (referred to as MGI) is committed to building core tools and technology to lead life science through intelligent innovation. With a focus on R&D, production and sales of DNA sequencing instruments, reagents, and related products, MGI provides real-time, panoramic, and full-life-cycle equipment and systems for precision medicine, precision agriculture, precision healthcare and other relevant industries. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation.

As of December 31, 2021, MGI has 2,050 employees, and 35% of whom are R&D personnel. Founded in 2016, MGI operates in more than 80 countries and regions, serving more than 1,300 customers. It has established scientific research and production bases, global training and service network in many countries and regions around the world. MGI is one of the few companies in the world that have the ability to independent develop and mass-produce clinical high-throughput gene sequencers. Providing real-time, comprehensive, life long solutions, its vision is to lead life science innovation.